Adjusted for cell proportions: FALSE PR **PNR** PR - PNR ADA ADA ADA enriched in B cells (I) (LI.M47.0) enriched in B cells (II) (LI.M47.1) plasma cells & B cells, immunoglobulins (LI.M156.0) enriched in B cells (VI) (LI.M69) plasma cells, immunoglobulins (LI.M156.1) -B cell surface signature (LI.S2) enriched in B cells (III) (LI.M47.2) enriched in T cells (I) (LI.M7.0) -T cell activation (I) (LI.M7.1) -T cell activation (III) (LI.M7.4) -T cell surface signature (LI.S0) -Direction of effect T cell differentiation (Th2) (LI.M19) -Down at week 14 T cell activation and signaling (LI.M5.1) -Not significant T cell activation (II) (LI.M7.3) -Gene module Up at week 14 cell cycle and transcription (LI.M4.0) -Effect size (AUC) enriched in activated dendritic cells/monocytes (LI.M64) -0.6 TBA (LI.M55) -0.7 blood coagulation (LI.M11.1) -8.0 viral sensing & immunity; IRF2 targets network (II) (LI.M111.1) -0.9 enriched in monocytes (IV) (LI.M118.0) enriched in activated dendritic cells (II) (LI.M165) -Monocyte surface signature (LI.S4) platelet activation - actin binding (LI.M196) cell adhesion (LI.M51) platelet activation & blood coagulation (LI.M199) enriched in myeloid cells and monocytes (LI.M81) -TLR and inflammatory signaling (LI.M16) enriched in neutrophils (I) (LI.M37.1) immune activation - generic cluster (LI.M37.0) enriched in monocytes (II) (LI.M11.0) --log10(FDR)